<![CDATA[Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab]]>

Phase 3durvalumabbevacizumabNeutral

AI Analysis

Summary

Jun Gong, MD presents the EMERALD-1 trial, a phase 3 randomized double-blind study evaluating transarterial chemoembolization combined with durvalumab, with or without bevacizumab, in patients with unresectable hepatocellular carcinoma amenable to embolization.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.00

hepatocellular carcinomaTACEimmunotherapyphase 3oncology

Related Companies

$AZN $RHHBY

Read the original article

Published by Cancer Network on August 7, 2026 12:05 PM

Read Original